Malignant Neoplasm — Trials

Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

90,662 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 20,108
Recruiting: 10,888
Ph III recruiting: 1,278
Growth YoY: +12.8%
Industry share: 20%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 29.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11,158)

clinicaltrialsPublishedShowing 51–100 of 1,278 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07513376	A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)(INTerpath-014)	recruiting	Phase 3	876	Merck Sharp & Dohme LLCINDUSTRY	18	Sep 28, 2026	clinicaltrials
NCT07525206	A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer(AndroMETa-CRC)	recruiting	Phase 3